The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM)

被引：48
作者：
Basile, Jan N. [1 ]
机构：
[1] Med Univ S Carolina, Seinsheimer Cardiovasc Hlth Program, Charleston, SC 29425 USA
来源：
JOURNAL OF DIABETES AND ITS COMPLICATIONS | 2013年 / 27卷 / 03期
关键词：
INADEQUATE GLYCEMIC CONTROL; DOUBLE-BLIND; BODY-WEIGHT; ADD-ON; DAPAGLIFLOZIN; MELLITUS; CANAGLIFLOZIN; METFORMIN; INSULIN; HYPERGLYCEMIA;
D O I：
10.1016/j.jdiacomp.2012.12.004
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Type 2 diabetes mellitus (T2DM) significantly increases morbidity and mortality from cardiovascular disease (CVD). Treatments for patients with T2DM have the potential to reduce cardiovascular (CV) risk. This review focuses on the potential of a new class of antidiabetic agents, the sodium glucose cotransporter 2 (SGLT2) inhibitors, to reduce CV rsk in patients with T2DM through reductions in hyperglycemia, blood pressure (BP), and body weight. The results of clinical trials of SGLT2 inhibitors are summarized and discussed. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码：280 / 286
页数：7
相关论文
共 72 条
  • [1] [Anonymous], J AM SOC NEPHROLOGY
  • [2] [Anonymous], DIABETOLOGIA
  • [3] [Anonymous], 2012, Diabetes Care, DOI DOI 10.2337/DC12-S004
  • [4] [Anonymous], 2011, National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the United States
  • [5] [Anonymous], 2011, 202293 FDA NDA
  • [6] Renal glucose reabsorption inhibitors to treat diabetes
    Bailey, Clifford J.
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2011, 32 (02) : 63 - 71
  • [7] Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
    Bailey, Clifford J.
    Gross, Jorge L.
    Pieters, Anne
    Bastien, Arnaud
    List, James F.
    [J]. LANCET, 2010, 375 (9733) : 2223 - 2233
  • [8] A New Approach to Glucose Control in Type 2 Diabetes: The Role of Kidney Sodium-Glucose Co-transporter 2 Inhibition
    Basile, Jan
    [J]. POSTGRADUATE MEDICINE, 2011, 123 (04) : 38 - 45
  • [9] Beest FJAP, 2008, CURR MED RES OPIN, V24, P2523, DOI [10.1185/03007990802336335, 10.1185/03007990802336335 ]
  • [10] Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
    Bolinder, Jan
    Ljunggren, Osten
    Kullberg, Joel
    Johansson, Lars
    Wilding, John
    Langkilde, Anna Maria
    Sugg, Jennifer
    Parikh, Shamik
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (03) : 1020 - 1031
12345678